National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing
about
Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell linesHuman rhabdomyosarcoma cell lines for rhabdomyosarcoma research: utility and pitfalls.Acid ceramidase is a novel drug target for pediatric brain tumors.Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia.Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program.The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.Bioactive lipids, LPC and LPA, are novel prometastatic factors and their tissue levels increase in response to radio/chemotherapyInitial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program.Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing programMetabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing programEfficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program.The Macrophage Inhibitor CNI-1493 Blocks Metastasis in a Mouse Model of Ewing Sarcoma through Inhibition of Extravasation.Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.Human rhabdomyosarcoma cells express functional erythropoietin receptor: Potential therapeutic implications.Initial testing (stage 1) of the phosphatidylinositol 3' kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program.The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicityPharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.Initial Testing of NSC 750854, a Novel Purine Analog, Against Pediatric Tumor Models by the Pediatric Preclinical Testing Program.Alveolar rhabdomyosarcoma - The molecular drivers of PAX3/7-FOXO1-induced tumorigenesisInitial testing (stage 1) of the anti-microtubule agents cabazitaxel and docetaxel, by the pediatric preclinical testing program.Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.What is new in rhabdomyosarcoma management in children?The impact of the written request process on drug development in childhood cancer.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.Targeted molecular radiotherapy of pediatric solid tumors using a radioiodinated alkyl-phospholipid ether analog.Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
P2860
Q38098914-1552C980-832E-4660-885B-693DA4B9CCCFQ54798448-C4E946BC-12EB-46A1-AB68-97F5F0185BD5Q54809015-E454CF20-4BBC-4208-B15F-1163AF3AC9E9Q54812148-556A8BD1-A203-48D5-85D8-FA9B54F8497FQ54812153-33CDBA6C-BF8C-4A62-A0BF-65949F1B781BQ54812155-80024B8F-6D92-4152-B44D-79E920CEC418Q54812160-CCF57DE3-3FA2-4244-BA9B-B26A09065FDAQ54812494-34A706F6-C743-44A7-8DDC-B4B712CD06CFQ54812496-D94868AF-23D3-4CA4-A027-62A968305746Q54812509-6C6C969C-A90E-4E81-802B-6B1926D8BC1CQ54812511-A4D062CA-63C4-4708-B384-71B4397ABD10Q54813969-BFDE4C03-D6D6-47EB-B478-D5C33400DDE0Q54899495-4A2E386B-9404-4955-8D4A-D6664ADAE311Q54906365-0A58E594-30F1-428D-A671-D15E21E4D430Q54907109-19EA244A-E649-4FDD-B61F-5D276D24A97EQ54907426-F9A75190-07E0-4C76-AEC8-FF5781BA6618Q54907501-0396B3A4-FEB5-4A76-AC0B-33F05CDCD6DDQ54907506-E68BCBA7-FBFA-49B6-81EC-8A10B67908A9Q54949198-4F62AF29-8097-4F0A-9BBF-C7F285D93F5CQ54949532-4D11BB04-101F-4CBF-BDF7-F924C3908B62Q54950333-D1413F55-A4E7-4FB6-9DB5-4839EEF6E6E9Q54950341-9D176D52-5C52-4A37-AB90-DCF23D43CB32Q54950346-8D8DC620-4143-400D-A6C7-C879D65B98DDQ54951304-B44DE803-B287-478F-81FA-BAE5A568D7FDQ54953524-B61683CE-366F-4CE7-8C99-D1A39AD22500Q54970705-C0DE2BA1-736C-4BE9-9D15-75D078E2D4D5Q54971816-A22A65EE-D7E8-4ABF-94F3-72F904D27D05
P1343
Q28535586-42A62D61-BE8A-4AA0-80BF-91894CDF2BEFQ30418118-44111201-67CC-4FAD-B248-E8145412643CQ33648644-D4EE1C4F-D9EB-4CE7-8467-9F0B83EB1C13Q34031153-16173C0D-68E5-4B99-BFA9-A9540A86A0A3Q34361391-8A97E48F-74B1-426C-A6F5-2CB1B362D58DQ34371357-441A95A6-A2FB-4D21-B199-2C25A3D44672Q34448863-44FB3CC7-0423-4613-9558-96FD22C4319DQ34475754-E90B58D3-2A30-4C91-9632-6A95215FDFC1Q34518525-F83FCF43-BD16-49B7-B787-A3708C18FBF9Q34561518-E5ED4DF7-6342-40AB-A334-210EB982BBA0Q34660299-9C98C266-0C6C-4887-8858-3AFFC88F5933Q34683835-1CB95326-C81E-4827-AABA-E2490857E56BQ34953372-C278B1F0-F65E-4C84-A749-C7F53FA3E1B2Q35005290-EDE911F1-3AA4-4E3E-A3B7-F62A2FDBE350Q35186275-B84E5CA5-2653-416E-B2B9-E11687EDBB08Q35513763-374D065A-3769-4C2D-AD34-C5E7239899EDQ35549470-2A7BE8CB-78AE-40AB-9259-BE3D5F76D8F5Q35599819-4C096A68-FE4D-455E-B580-E8242C69449CQ35622015-969CEF4E-E590-43BC-961E-25C06EDBBD57Q35739550-6A553675-16A2-48E7-ABAD-F8DF208FC479Q35791105-8699C23D-C22F-4376-81A8-9868819C8CA1Q35879521-C6C1A840-1257-4256-8941-67EF8F41A595Q36104739-9A4EACE7-9FA2-48DB-A62E-AC139C53974FQ36140572-1420C026-D8BB-4FAF-A967-2C085C9072A8Q36386881-C83491C8-59BE-4B34-83C7-20F4E24B933BQ36416243-96277A43-F095-4066-B361-3CCD0A0FCB30Q36489494-486719F5-7180-4686-9FBB-2569F6E763CCQ36495432-5C0B5792-041F-48B2-8A48-57015F328E86Q36588372-D8709FE9-1627-497E-BB8F-3CA83F2A660CQ36592309-E27D5807-17A6-407A-9059-6BA274CBBE0EQ36728942-82CB933C-1DF4-4302-A1A7-53CE2B9851B4Q37633429-0A967E69-F1BC-4483-A5D9-4ACA507A178BQ37724891-7A8DE39D-9011-465A-9F8C-C83800FEAA0FQ38050831-D9EDAC80-7954-4E87-859B-AD19593CF7D4Q38075541-EF19D954-7FD6-46E9-AD5A-44C2F0A9ECCEQ38113988-DC9987A5-BCE7-425D-8248-07906935F986Q38621653-1E8F19A6-1D13-4AE0-AE59-E707A9FA36A5Q38659292-86DCA80D-8B66-4C59-A4C5-A6EC91C3D1C3Q38736349-DC85D184-F4B5-458E-9536-E789FB4654F0Q38744639-71254227-3051-41BF-B68C-69116EC36822
P2860
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@ast
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@en
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@nl
type
label
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@ast
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@en
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@nl
prefLabel
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@ast
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@en
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@nl
P2093
P2860
P4510
P356
P1476
National Cancer Institute pedi ...... in vitro cytotoxicity testing
@en
P2093
Christopher L Morton
Malcolm A Smith
Nino Keshelava
Peter J Houghton
P2860
P304
P356
10.1002/PBC.22801
P577
2010-10-04T00:00:00Z